Medication info
Clopidogrel Tablets (Clopidogrel Hydrochloride)

Clopidogrel Tablets (Clopidogrel Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Clopidogrel Bisulfate›97.875mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201206954 · Approved 2012.09.26 · Insurance code 653402630

Summary

Main use
Improvement of symptoms of acute coronary syndrome and atherosclerosis, prevention of thromboembolism in atrial fibrillation
Who takes it
Adults
Adult dose
○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer 75 mg of clopidogrel orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start treatment on the first day with a loading dose of 300 mg of this medicine once daily, followed by a maintenance dose of 75 mg orally once daily. Aspirin 75 ~ 325 mg should be administered concomitantly with this medicine once daily. 3. For patients with atrial fibrillation, administer 75 mg of this medicine orally once daily. Aspirin 75 ~ 100 mg should be administered concomitantly with this medicine once daily. ○ Patients with renal impairment : Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment : Treatment experience in patients with moderate liver disease with a bleeding diathesis is limited. This medicine may be taken with or without food.

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of symptoms of acute coronary syndrome and atherosclerosis, prevention of thromboembolism in atrial fibrillation

  • Ischemic stroke
  • myocardial infarction
  • peripheral arterial disease
  • acute coronary syndrome
  • unstable angina
  • non-Q-wave myocardial infarction
  • cardiovascular anomalies
  • stroke
  • refractory ischemia
  • vascular risk factors
  • bleeding risk
  • atrial fibrillation
View approved original text

This medicine is used to improve the condition of adult patients with atherosclerotic symptoms such as ischemic stroke, myocardial infarction, and peripheral arterial disease. Additionally, it helps alleviate atherosclerotic symptoms while reducing the risks of death, myocardial infarction, and stroke due to cardiovascular anomalies in patients with acute coronary syndrome, particularly those with unstable angina or non-Q-wave myocardial infarction. Furthermore, it has the effect of reducing the risk of stroke and thromboembolism in patients with atrial fibrillation, where vitamin K antagonists are not suitable. Due to these effects, positive therapeutic effects can be expected in various cardiovascular diseases. Therefore, this medicine is used to improve and manage cardiovascular risk factors associated with atherosclerotic symptoms.

How to take

Adult dose

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer 75 mg of clopidogrel orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start treatment on the first day with a loading dose of 300 mg of this medicine once daily, followed by a maintenance dose of 75 mg orally once daily. Aspirin 75 ~ 325 mg should be administered concomitantly with this medicine once daily. 3. For patients with atrial fibrillation, administer 75 mg of this medicine orally once daily. Aspirin 75 ~ 100 mg should be administered concomitantly with this medicine once daily. ○ Patients with renal impairment : Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment : Treatment experience in patients with moderate liver disease with a bleeding diathesis is limited. This medicine may be taken with or without food.

Precautions

This medicine is a drug that inhibits the aggregation of platelets in the blood to prevent thrombus formation. This drug is converted into an active metabolite by a specific enzyme, CYP2C19, in the liver, and its efficacy may be reduced in individuals with genetically impaired function of this enzyme. If the concentration of the active metabolite becomes too high, the risk of bleeding may increase; therefore, it is important to avoid taking it with drugs that activate CYP2C19. Patients with allergies to this drug or its components, those with bleeding, patients with severe liver damage, and nursing mothers should not take this medicine. Patients at high risk of bleeding, patients with poor liver or kidney function, the elderly, and underweight patients should use this drug cautiously, and it is recommended to discontinue the drug 5 to 7 days before any scheduled surgery. Because this drug may increase the risk of bleeding, any bleeding symptoms should be reported immediately to healthcare professionals, and caution is needed when combined with other medications that have a risk of bleeding. During the course of this medication, regular blood tests should be conducted to monitor for bleeding or blood abnormalities. Pregnant women should carefully consider the use of this drug, unless in an emergency, and it is recommended to discontinue medication around the time of delivery due to a risk of bleeding. Nursing mothers should carefully assess whether to breastfeed while taking this drug, as it may be excreted in breast milk. In cases of overdose, bleeding time may be prolonged, and bleeding complications may occur, so it is imperative to adhere to the prescribed dosage. The safety and efficacy of this drug have not been established in children, so its use is not recommended. During the course of this medication, keep a close watch for any unusual symptoms such as bleeding, allergic reactions, gastrointestinal disturbances, skin rashes, headache, dizziness, abdominal pain, dyspepsia, diarrhea, nausea, hypercholesterolemia, arthralgia, back pain, bruising/sprains, epistaxis, depression, upper respiratory tract infections, rhinitis, bronchitis, cough, rash, pruritus, urinary tract infections, decreased motor function, tremors, voice disturbances, abnormal gait, hyperkinesia, ataxia, perceptual abnormalities, constipation, vomiting, and insomnia.

Side effects

Hemorrhage, gastrointestinal bleeding, bleeding requiring hospitalization, purpura, contusion, hematoma, epistaxis, hematoma, hematuria, intraocular hemorrhage, intracranial hemorrhage, significant bleeding, life-threatening bleeding, fatal hemorrhage, hemorrhagic stroke, requirement for blood transfusion, significant functional impairment, intraocular hemorrhage accompanied by substantial visual loss, mild bleeding, neutropenia, agranulocytosis, aplastic anemia, thrombocytopenia, skin and skin appendages adverse reactions, chest pain, accidental injury, influenza-like illness, pain, fatigue, edema, hypertension, headache, dizziness, abdominal pain, dyspepsia, diarrhea, nausea, hypercholesterolemia, arthralgia, back pain, depression, upper respiratory infection, shortness of breath, rhinitis, bronchitis, cough, rash, pruritus, urinary tract infection, syncope, palpitations, asthenia, fever, hernia, heart failure, atrial fibrillation, leg cramps, sensory deficit, neuralgia, paresthesia, dizziness, constipation, vomiting, increased liver enzymes, gout, hyperuricemia, arthritis, arthrosis, anxiety, insomnia, anemia, pneumonia, sinusitis, eczema, skin ulcer, cystitis, cataract, conjunctivitis, gynecomastia, decreased motor function, tremor, speech disorder, abnormal gait, hyperkinesia, ataxia, dysesthesia, insomnia, depression, amnesia, confusion, abnormal behavior, rigidity, facial edema, purpura disease, melena, hematoma, thrombocytopenia, cerebral hemorrhage, gingival bleeding, visual disturbances, visual field defects, dry eyes, transient blindness, congestion, tinnitus, dysuria, polyuria, non-protein nitrogen increase, uremia, increase in blood urea nitrogen, hypoglycemia, ALT elevation, liver function abnormalities, leg edema, arrhythmia, bradycardia, palpitations, contact dermatitis, elevated prostate-specific antigen, anorexia, weight loss, weight gain, flushing, hiccups, dysphagia, tongue disease, gynecomastia, elevated PSA, cholecystitis, hematemesis, spinal hematoma, thrombocytopenia, thrombocytopenic purpura, vasculitis, hypotension, bronchospasm, interstitial pneumonia, eosinophilic pneumonia, colitis, pancreatitis, gastritis, stomatitis, hepatitis, acute liver failure, varicella, erythematous rash, maculopapular rash, urticaria, renal dysfunction, acute renal failure, allergic symptoms, ischemic necrosis, hemorrhagic arthropathy, hematuria, hemoptysis, retroperitoneal hemorrhage, surgical wound bleeding, pulmonary hemorrhage, anaphylaxis-like reaction, serum sickness, confusion, hallucination, taste disturbance, loss of taste, angioedema, vesicular dermatitis, drug-induced hypersensitivity syndrome, eosinophilia, drug rash accompanied by systemic symptoms, lichenoid eruption, glomerulopathy, fever

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it is best to store the medication at room temperature between 1 and 30 degrees Celsius, away from extreme heat or cold.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.